Boston Scientific has initiated a study to evaluate its fully resorbable scaffold technology. FAST (Fully absorbable scaffold feasibility study) is a prospective, single-arm study designed to assess the safety and performance of this next-generation scaffold for the treatment of atherosclerotic coronary lesions.
According to a press release, the first patients in the study were enrolled by primary investigator Ian Meredith (director of MonashHeart, Monash Medical Centre in Melbourne, Australia). The press release reports that the aim is to enrol up to 30 patients in the study.
It adds that the resorbable polymer scaffold incorporates several key design elements from Boston Scientific’s everolimus-eluting stent with a biodegradable polymer (Synergy) and also features a delivery system built with Boston Scientific’s “expertise designed to facilitate improved acute performance”.
Meredith says: “By virtue of its unique design properties, incorporating thinner struts and enabling greater stent expansion while maintaining radial strength, this fully resorbable scaffold technology may potentially overcome a number of limitations with first-generation absorbable scaffolds.”
“We are taking the best of our Synergy stent and applying it to our new, fully resorbable scaffold technology. We continue to invest in meaningful innovations designed to provide better outcomes for patients with coronary artery disease,” notes Kevin Ballinger, president, Interventional Cardiology, Boston Scientific.
The fully resorbable scaffold technology is under development and is not available for sale.